Avelumab and Merkel Cell Carcinoma: Examining the Evidence

From General Health to Occupational Exposure

The legacy of general health and science information has long provided a foundational framework for understanding broad population-level risks and preventive measures. Within this context, public health messaging has historically emphasized lifestyle factors, environmental exposures, and the importance of vaccination in reducing disease burden. This established body of knowledge serves as a critical starting point for examining more specific, emerging concerns in occupational and therapeutic settings. As we pivot from this general health perspective, attention now turns to the domain of mass production environments, where workers may encounter unique chemical and biological agents. Among these, the monoclonal antibody Avelumab has been investigated for its potential role in modulating immune responses, particularly in relation to cancer risk. Recent studies have begun to explore the association between Avelumab exposure and the incidence of Merkel Cell Carcinoma, a rare but aggressive skin cancer. While the general public may be familiar with skin cancer prevention through sun safety, the occupational context introduces a distinct set of variables, including chronic exposure to immunomodulatory agents. This transition from broad health literacy to a focused occupational exposure concern underscores the need for rigorous epidemiological surveillance and risk assessment in manufacturing settings where such compounds are handled.

Avelumab: Mechanism and Approved Use

Avelumab (Bavencio) is a fully human IgG1 monoclonal antibody that functions as an immune checkpoint inhibitor by targeting programmed cell death ligand 1 (PD-L1) (https://pubmed.ncbi.nlm.nih.gov/29799096/). It has been approved in the United States, the European Union, and Japan for the treatment of metastatic Merkel cell carcinoma (MCC), a rare and aggressive neuroendocrine cutaneous malignancy with poor prognosis (https://pubmed.ncbi.nlm.nih.gov/33439294/; https://pubmed.ncbi.nlm.nih.gov/29799096/). This approval was based on the two-part, single-arm, phase II JAVELIN Merkel 200 trial, in which confirmed objective responses were observed in approximately one-third of patients with chemotherapy-refractory metastatic MCC treated with avelumab (https://pubmed.ncbi.nlm.nih.gov/29799096/). Avelumab is thus the first therapeutic agent specifically approved for this indication, and it is approved for use independent of line of treatment (https://pubmed.ncbi.nlm.nih.gov/29799096/).

Merkel Cell Carcinoma: Etiology and Epidemiology

Merkel cell carcinoma is associated with chronic exposure to ultraviolet light and the Merkel cell polyomavirus, with approximately 80% of cases caused by the human Merkel cell polyomavirus and the remaining 20% induced by UV light leading to mutations (https://pubmed.ncbi.nlm.nih.gov/35877101/; https://pubmed.ncbi.nlm.nih.gov/34445385/). The incidence rate of MCC is increasing, and the disease is associated with high rates of recurrence and mortality (https://pubmed.ncbi.nlm.nih.gov/35877101/). Immune checkpoint inhibitors, including avelumab (anti-PD-L1) and pembrolizumab (anti-PD-1), offer durable responses and significant clinical benefit in advanced MCC, with response rates to PD-1/PD-L1 inhibition of up to 62% (https://pubmed.ncbi.nlm.nih.gov/36450381/; https://pubmed.ncbi.nlm.nih.gov/35877101/). However, approximately 50% of patients with advanced MCC treated with immune checkpoint inhibitors progress on therapy, and 50% of patients do not respond or develop immune-related adverse events due to diverse mechanisms, such as down-regulation of MHC complexes or the induction of anti-inflammatory cytokines (https://pubmed.ncbi.nlm.nih.gov/35877101/; https://pubmed.ncbi.nlm.nih.gov/34445385/).

Causation and Risk: What the Evidence Shows

The mechanistic pathways linking avelumab to Merkel cell carcinoma are centered on its role as an immune checkpoint inhibitor. By blocking PD-L1, avelumab enhances T-cell responses against tumor cells, which is the intended therapeutic effect in MCC (https://pubmed.ncbi.nlm.nih.gov/34445385/). However, this immune activation can also lead to immune-related adverse events, which are a known risk of checkpoint inhibitor therapy. The evidence does not suggest that avelumab causes Merkel cell carcinoma; rather, it is used to treat the disease. The risk narrative regarding avelumab and MCC causation is therefore not about the drug inducing the cancer, but about its efficacy and safety in treating an existing malignancy, as well as the management of patients who become refractory to avelumab therapy. For patients who are refractory to avelumab, treatment options are limited. Studies have investigated the use of combined ipilimumab plus nivolumab in avelumab-refractory Merkel cell carcinoma. In a retrospective study at three academic sites in Germany, three out of five patients with metastatic MCC refractory to avelumab responded to combined ipilimumab plus nivolumab according to RECIST 1.1 criteria (https://pubmed.ncbi.nlm.nih.gov/33439294/). A multicenter study of the prospective skin cancer registry ADOREG similarly reported on ipilimumab plus nivolumab in avelumab-refractory MCC, noting that immune checkpoint inhibition has significantly improved treatment outcomes in metastatic disease (https://pubmed.ncbi.nlm.nih.gov/36450381/). Another retrospective study of ipilimumab plus nivolumab in anti-PD-L1/PD-1 refractory MCC confirmed that despite advances in systemic therapy, about 50% of patients with advanced MCC treated with immune checkpoint inhibitors progress on therapy (https://pubmed.ncbi.nlm.nih.gov/35877101/). Regarding the adequacy of warnings, the evidence indicates that avelumab is approved for metastatic MCC and that its use is associated with a risk of immune-related adverse events. The timeline between exposure and documented harm is relevant to the development of immune-related adverse events, which can occur during treatment. However, the evidence does not provide specific data on the timing of such events relative to avelumab initiation. For causation-related considerations, affected patients should be aware that avelumab is a treatment for MCC, not a cause of the disease, and that the primary risks are related to immune-related adverse events and the possibility of disease progression despite therapy.

Summary and Clinical Implications

In summary, avelumab is an established treatment for metastatic Merkel cell carcinoma, with evidence supporting its efficacy in a subset of patients. The risk of immune-related adverse events is a known consequence of its mechanism of action, and for patients who become refractory, alternative immunotherapies such as ipilimumab plus nivolumab may offer benefit. The evidence does not support a causal link between avelumab and the development of Merkel cell carcinoma; rather, the drug is used to treat the condition.

Important Notice

This page is for educational and informational purposes only. It does not provide medical diagnosis, treatment, or legal advice. Consult licensed clinicians and qualified attorneys for case-specific decisions.

Community Resource & Benefit Desk

Request archival records or inquire about member-exclusive transition and benefit programs.

Frequently Asked Questions

Does avelumab cause Merkel cell carcinoma?

No, the evidence does not suggest that avelumab causes Merkel cell carcinoma. Avelumab is an immune checkpoint inhibitor used to treat metastatic Merkel cell carcinoma. Its mechanism of action involves blocking PD-L1 to enhance T-cell responses against tumor cells, which is the intended therapeutic effect. The primary risks associated with avelumab are immune-related adverse events and the possibility of disease progression despite therapy.

What are the treatment options for patients who become refractory to avelumab?

For patients with metastatic Merkel cell carcinoma who become refractory to avelumab, studies have investigated the use of combined ipilimumab plus nivolumab. Retrospective studies have shown that some patients respond to this combination therapy according to RECIST 1.1 criteria (https://pubmed.ncbi.nlm.nih.gov/33439294/; https://pubmed.ncbi.nlm.nih.gov/36450381/). However, about 50% of patients with advanced MCC treated with immune checkpoint inhibitors may progress on therapy (https://pubmed.ncbi.nlm.nih.gov/35877101/).

Does submitting information create an attorney-client relationship?

No. Submission requests an initial records screening only and does not create an attorney-client relationship.

Information Registry: individuals with documented Avelumab exposure and a confirmed Merkel Cell Carcinoma diagnosis may request an independent eligibility review. [Begin Assessment]

References

Check Whether Your Situation Qualifies

Free and confidential. No obligation — an initial records screening only.

This page is for educational and informational purposes only and is not medical or legal advice. Consult a licensed professional for case-specific guidance.